Lupin has received approval for divestment of its entire equity interest, representing 99.82% of the issued and paid up capital, in Kyowa Pharmaceutical Industry, Japan, a step-down material subsidiary of the Company, by Nanomi BV, a wholly owned material subsidiary of the Company, by way of sale of shares, to Plutus, Japan (an entity affiliated with Unison Capital Partners IV, LPS and Unison Capital Partners IV(F), LP) at an enterprise value of JPY 57,361 million on terms and conditions agreed under a share purchase agreement. The Board of Directors of the Company at its meeting held on November 11, 2019 has approved the same.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: